ENDO 09: The Highest Quality Scientific Program
ENDO 09 will build upon the tradition of excellence of past annual meetings with an outstanding program, including some key new sessions that will debut at the Washington meeting. Full Story...
The Endocrine Society's Continuing Medical Education Services (CMES)
The Endocrine Society is known for scientific excellence and a prestigious reputation. Since 1996, the Society's Continuing Medical Education Services (CMES) has conducted more than 400 CMES programs, reaching over 100,000 physicians. CMES delivers outstanding quality through: Full Story...
The Hormone Foundation Develops Innovative Ways to Reach Patients
The Hormone Foundation, the public education affiliate of The Endocrine Society, develops educational materials and programs for patients and the general public on a variety of endocrine disorders. Full Story...
Reach the Thought Leaders in Endocrinology at ENDO 09
ENDO has proven to be the endocrinology meeting you do not want to miss. 70% of our attendees are physicians or allied health professionals. In fact, over 50% of our attendees work in clinics, independent practices and hospitals. ENDO offers a unique and exciting opportunity for you to connect with the most influential thought leaders in endocrinology. Full Story...
Exhibit & Advertising Opportunities
Exhibit at the World’s Largest Gathering of Clinical Endocrinologists. 90 % of ENDO attendees visit the exhibits and spend an average of 4 hours on the floor. Reach Endocrinology’s Thought Leaders by exhibiting at ENDO 09. Please contact Darrin Scherago at 201-653-4777 (Ext. 20) or darrins@scherago.com for more information.
Improving the State of the Clinical Research Enterprise
The burgeoning regulatory burden of doing clinical research in the United States increasingly impacts the ability of companies and individual researchers to perform sound, expeditious clinical studies. While all clinical scientists are affected by the seemingly endless regulatory requirements, pediatric researchers and those engaged in multisite trials are especially hard-hit as a result of additional layers of regulation for research involving children and inconsistent IRB interpretation of regulations among sites, respectively. Full Story...
The Corporate Liaison Board Hosts 9th Annual Forum at ENDO 09
The 2008 CLB Program "Pathways in the Control of Metabolism: Emerging Links" was extremely successful, with over 340 attendees. 94% of attendees reported that they would recommend the program to their colleagues and 88% of attendees rated the speakers' delivery, knowledge and organization of the presentation as above average or excellent. Full Story...
The Endocrine Society Publishes Seven Clinical Practice Guidelines
To date, seven Clinical Practice Guidelines (CPGs) have been published and three other guidelines have been approved by The Endocrine Society's Council. There are currently eight other CPGs in various stages of development; including two CPGs that are being revised. Full Story...
Society Leadership Meets with NIH Institute Directors
The Society leadership, including President Margaret Shupnik, PhD, and Vice Presidents Henry Kronenberg, MD, and Lynette Nieman, MD, had the opportunity to discuss topics of mutual interest with National Institutes of Health (NIH) directors on April 21, 2008 and May 21, 2008. Full Story...
Society Works with Bill Sponsors to Fix DXA Payment Cuts
After months-long debate, on Wednesday July 9, Senators voted 69-30 to invoke cloture and limit discussion, allowing H.R. 6331, the "Medicare Improvements for Patients and Providers Act of 2008," to be passed by unanimous consent. The bill blocks physician payment cuts and provides a 0.5 percent increase for payments through the rest of 2008, and another 1.1 percent increase in 2009. Full Story...
Society President-Elect Testifies Before FDA Advisory Panel
The Endocrine Society President-Elect, Robert Vigersky, MD, testified before the Food and Drug Administration (FDA) Center for Drug Evaluation and Research's Endocrinologic and Metabolic Drugs Advisory Committee on July 2, 2008 about the need to include long-term cardiovascular impact research in the study of all new diabetes drugs.
